AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase inhibitor relebactam – has been cleared by the FDA for adults with ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Together, they’re being studied as a potential treatment option for serious bacterial infections caused by antibiotic-resistant gram-negative bacteria, including Extended Spectrum Beta-lactamase ...

She joined the Palzkill lab in 2022 and currently focuses on the beta-lactamase inhibitory protein and mutating key residues for more potent inhibition across many beta-lactamases.

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...